早期创伤性脑损伤中凝血生物标志物、颅内出血类型与氨甲环酸治疗的关系
本文为院前TXA治疗TBI试验的二次分析,纳入格拉斯哥昏迷评分<13且收缩压≥90 mmHg、院前盲法随机接受2 g TXA团注、1 g团注+1 g输注或安慰剂的783例患者。464例存在颅内出血,其中混合型302例。纤溶活性标志物D-二聚体、纤溶酶-α2-抗纤溶酶复合物(PAP)和凝血酶-抗凝血酶复合物(TAT)在任何颅内出血和混合型颅内出血中显著升高。较高的D-二聚体、PAP、TAT水平与出院及6个月时死亡率增加、Glasgow结局扩展评分和残疾评定量表恶化相关。PAP与TXA治疗相关,较高的初始TXA团注剂量对应较低的PAP水平。
要点
- 在早期TBI患者中,D-二聚体、PAP、TAT升高与存在任何颅内出血及混合型颅内出血相关。
- 较高的D-二聚体、PAP、TAT水平与出院和6个月时死亡率增加及Glasgow结局扩展评分、残疾评定量表恶化相关。
- 仅PAP与TXA治疗相关,较高的初始TXA团注剂量对应较低的PAP水平。
- 作者认为未来研究应检验PAP作为TXA反应性潜在标志物的效用。
- 证据等级:治疗/护理管理;Level III。
适用人群与场景
- 院前创伤性脑损伤患者,格拉斯哥昏迷评分<13且收缩压≥90 mmHg,院前盲法随机接受2 g TXA团注、1 g TXA团注+1 g TXA输注或安慰剂团注+输注。
研究设计与关键结果
- 研究类型:院前TXA治疗TBI试验的二次分析;样本量783例,其中464例存在颅内出血(硬膜外5例、硬膜下40例、蛛网膜下腔84例、脑室内7例、脑实质内26例、混合型302例、任何颅内出血464例),319例无颅内出血。
- 纤溶活性标志物D-二聚体、PAP和TAT在任何颅内出血和混合型颅内出血存在时显著升高。
- 较高的D-二聚体、PAP和TAT水平与出院和6个月时死亡率增加及Glasgow结局扩展评分、残疾评定量表恶化相关。
- PAP与TXA治疗相关,较高的初始TXA团注剂量对应较低的PAP水平。
证据类型、等级与局限
- 证据类型:随机对照试验的二次分析;证据等级:治疗/护理管理;Level III。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为未来研究应检验PAP作为TXA反应性潜在标志物的效用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Although a prehospital 2 g bolus of tranexamic acid (TXA) has been associated with decreased mortality in patients with traumatic intracranial hemorrhage (ICH), the underlying mechanism remains controversial. We investigated whether early coagulation biomarkers are associated with ICH type, prehospital TXA treatment, and outcomes in patients with early traumatic brain injury (TBI).
METHODS: We conducted a secondary analysis of the Prehospital TXA for TBI trial (Glasgow Coma Scale score of <13 and systolic blood pressure of ≥90 mm Hg in patients blindly randomized prehospital to either a 2 g TXA bolus, 1 g TXA bolus plus 1 g TXA infusion, or placebo bolus plus infusion). Intracranial hemorrhage types were categorized as extradural, subdural, subarachnoid, intraventricular, intraparenchymal, mixed, any ICH, and no ICH. Outcomes including Glasgow Outcome Score-Extended, Disability Rating Score, and mortality were examined at discharge and 6 months. Associations between biomarkers, ICH type, TXA treatment group, and outcomes were examined.
RESULTS: Of 783 patients, 464 had ICH (5 extradural, 40 subdural, 84 subarachnoid, 7 intraventricular, 26 intraparenchymal, 302 mixed, 464 any ICH), and 319 had no ICH. Three markers of fibrinolytic activity (D-dimer, plasmin-α2-antiplasmin complex [PAP], and thrombin-antithrombin complex [TAT]) were significantly increased in the presence of any ICH and mixed ICH. Higher D-dimer, PAP, and TAT levels were associated with increased mortality, and worse Glasgow Outcome Score-Extended and Disability Rating Score at discharge and 6 months. Plasmin-α2-antiplasmin complex was associated with TXA treatment, with lower PAP levels associated with the higher initial TXA bolus dose.
CONCLUSION: In patients with early TBI, D-dimer, PAP, and TAT are associated with the presence of any ICH and mixed ICH. Higher D-dimer, PAP, and TAT levels are associated with neurologic outcomes. Only PAP is associated with TXA treatment. Future studies should examine the utility of PAP as a potential marker for TXA responsiveness.
LEVEL OF EVIDENCE: Therapeutic/Care Management; Level III.
参考来源
- Minoza KG, Brito AM, Loss L, et al. Association between coagulation biomarkers, intracranial hemorrhage types, and tranexamic acid treatments in early traumatic brain injury. J Trauma Acute Care Surg. 2025. PMID: 40490870. doi:10.1097/TA.0000000000004669
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。